Table 3.
MSCs based clinical trails.
| Liver diseases | Intervention Model | Estimated Enrollment | Source of MSCs | Route | Phase | Dose | Date | NTC number |
|---|---|---|---|---|---|---|---|---|
| Acute-on-Chronic Liver Failure | Parallel Assignment | 45 | N/A | Intravenous (peripheral vein) | Phase 1 and Phase 2 | once a week for 4 weeks, 1-10 × 105 cell/kg | 2019 | NCT03863002 |
| Acute-on-chronic Liver Failure | Parallel Assignment | 200 | N/A | Intravenous (peripheral vein) | N/A | 3 times at week 0, 4 and 8, 1 × 106 cell/kg | 2018 | NCT03668171 |
| Alcoholic Liver Cirrhosis | Single Group Assignment | 10 | Bone Marrow | Hepatic Artery injection | Phase 1 | A single dose of 4.5-5.5 × 107 cell | 2019 | NCT03838250 |
| Decompensate Cirrhotic Patients With Pioglitazone | Single Group Assignment | 3 | Bone Marrow | Intravenous (portal vein) | Phase 1 | 2 doses at with week intervals | 2014 | NCT01454336 |
| Decompensated Alcoholic Cirrhosis | Sequential Assignment | 36 | Umbilical Cord | Intravenous | Phase 1 | 0.5-2 × 106 cell/kg | 2021 | NCT05155657 |
| Decompensated Hepatitis B Cirrhosis | Single Group Assignment | 30 | Umbilical Cord | Intravenous | N/A | 2 doses with 24 week intervals, 1 × 108 cell | 2021 | NCT05106972 |
| Decompensated liver Cirrhosis | Parallel Assignment | 240 | Umbilical Cord | Intravenous | Phase 2 | 3 doses at week 0, week 4, week 8, 6 × 107 cell/kg | 2021 | NCT05121870 |
| Decompensated Liver Cirrhosis | Parallel Assignment | 45 | Umbilical Cord | Intravenous | Phase 1 and Phase 2 | 3 doses with 4 week intervals, 0.5 × 106 cell/kg | 2011 | NCT01342250 |
| End-stage Liver Disease (Cirrhosis) | Single Group Assignment | 30 | N/A | Intravenous | Phase 1 and Phase 2 | N/A | 2018 | NCT03460795 |
| HBV-Related Acute-on-Chronic Liver Failure | Parallel Assignment | 261 | Umbilical Cord Blood | Intravenous (peripheral vein) | Phase 2 |
|
2016 | NCT02812121 |
| HBV-related Liver Cirrhosis | Parallel Assignment | 240 | Umbilical cord | Intravenous | Phase 1 and Phase 2 | 1 × 106 cell/kg | 2012 | NCT01728727 |
| Hepatitis B mediated Liver Cirrhosis | Single Group Assignment | 12 | Umbilical Cord | Intravenous | Phase 1 and Phase 2 | A single dose of 1 × 108 cell | 2020 | NCT04357600 |
| Liver Cirrhosis | Single Group Assignment | 30 | Bone marrow | Intravenous (peripheral or the portal vein) | Phase 1 and Phase 2 | 3-4 × 107 | 2007 | NCT00420134 |
| Liver Cirrhosis | Single Group Assignment | 50 | Menstrual Blood | Intravenous | Phase 1 and Phase 2 | 4 time in 2 week 1 × 106 cell/kg | 2012 | NCT01483248 |
| Liver Cirrhosis | Parallel Assignment | 200 | Umbilical Cord | Intravenous | Phase 2 | 3 doses with 3 week intervals, 1 × 106 cell/kg | 2019 | NCT03945487 |
| Liver Cirrhosis | Single Group Assignment | 20 | bone marrow | Intravenous | Phase 1 and Phase 2 | A single dose of 0.5 - 1×106 cell/kg | 2018 | NCT03626090 |
| Liver Cirrhosis | Parallel Assignment | 266 | Umbilical Cord | Intravenous | Phase 1 and Phase 2 | 3 doses with 4 week intervals, 0.5 × 106 cell/kg | 2018 | NCT01220492 |
| Liver Cirrhosis | Single Group Assignment | 4 | Adipose tissue | Intrahepatic Arterial Administration | N/A | N/A | 2010 | NCT01062750 |
HBV, Hepatitis B virus; MSCs, Mesenchymal stromal/stem cells; EVs, Extracellular vesicles; TGF-β, Transforming growth factor-beta; NF-kB, Nuclear factor kappa-B; MMPs, Matrix metalloproteinase; NLRP, Nucleotide-binding oligomerization domain; ALT, alanine aminotransferase; AST, Aspartate transaminase; ALP, Alkaline Phosphatase; BM, Bone marrow; UC, umbilical cord; AD, adipose tissue; N/A, Not Applicable.